Abstract：
BACKGROUND: To evaluate the long-term effects of intense pulsed light (IPL) therapy on patients with dry eye disease (DED) associated with meibomian gland dysfunction (MGD).
METHODS: A retrospective case series was performed with 110 participants undergoing IPL therapy. Assessments included the eye fitness test (EFT) to gauge subjective symptoms, along with objective measures using the Tearcheck® device (ESW Vision, Houdan, France) noninvasive first breakup time (NIFBUT), noninvasive average breakup time (NIABUT), central tear meniscus height (CTMH), thinnest tear meniscus height (TTMH), and ocular surface inflammatory risk evaluation (OSIE) assessed using the SCHWIND SIRIUS device (SCHWIND eye-tech-solutions GmbH, Kleinostheim, Germany).
RESULTS: This study documented significant improvements in subjective and objective symptoms associated with DED and MGD. Subjective symptoms measured by the EFT showed an average increase of 9.74 points (range -10 to 28, standard deviation [SD] ± 7.54), indicating reduced symptoms. Objective measures of tear film stability, represented by NIABUT, increased by an average of 4.04 s (range -15.00 to 14.40, SD ± 4.91). Tear film stability evaluation (TFSE) scores decreased by 229.12 points on average (range -1775 to 528, SD ± 384.94), suggesting enhanced tear film stability. OSIE type 1 showed a reduction in inflammation, with a percentage decrease of 4.98% (range -45 to 5, SD ± 7.33). Additionally, OSIE capture time decreased by 3.25 s on average (range -27 to 22, SD ± 10.35), further indicating an improvement in ocular surface health.
CONCLUSIONS: IPL therapy was shown to be a promising, noninvasive approach for improving quality of life in patients with DED by effectively managing symptoms and stabilizing tear film. The findings support the use of IPL as a sustainable treatment modality for DED associated with MGD.
METHODS: A retrospective case series was performed with 110 participants undergoing IPL therapy. Assessments included the eye fitness test (EFT) to gauge subjective symptoms, along with objective measures using the Tearcheck® device (ESW Vision, Houdan, France) noninvasive first breakup time (NIFBUT), noninvasive average breakup time (NIABUT), central tear meniscus height (CTMH), thinnest tear meniscus height (TTMH), and ocular surface inflammatory risk evaluation (OSIE) assessed using the SCHWIND SIRIUS device (SCHWIND eye-tech-solutions GmbH, Kleinostheim, Germany).
RESULTS: This study documented significant improvements in subjective and objective symptoms associated with DED and MGD. Subjective symptoms measured by the EFT showed an average increase of 9.74 points (range -10 to 28, standard deviation [SD] ± 7.54), indicating reduced symptoms. Objective measures of tear film stability, represented by NIABUT, increased by an average of 4.04 s (range -15.00 to 14.40, SD ± 4.91). Tear film stability evaluation (TFSE) scores decreased by 229.12 points on average (range -1775 to 528, SD ± 384.94), suggesting enhanced tear film stability. OSIE type 1 showed a reduction in inflammation, with a percentage decrease of 4.98% (range -45 to 5, SD ± 7.33). Additionally, OSIE capture time decreased by 3.25 s on average (range -27 to 22, SD ± 10.35), further indicating an improvement in ocular surface health.
CONCLUSIONS: IPL therapy was shown to be a promising, noninvasive approach for improving quality of life in patients with DED by effectively managing symptoms and stabilizing tear film. The findings support the use of IPL as a sustainable treatment modality for DED associated with MGD.
摘要：
背景：评估强脉冲光（IPL）治疗对干眼症（DED）伴睑板腺功能障碍（MGD）患者的长期影响。
方法：对110名接受IPL治疗的参与者进行了回顾性病例系列研究。评估包括眼睛体能测试（EFT）以评估主观症状，以及使用Tearcheck®设备的客观测量(ESW视觉，胡丹,法国）非侵入性首次分手时间（NIFBUT），无创平均破裂时间(NIABUT)，中央撕裂半月板高度（CTMH），最薄泪液弯月面高度（TTMH），和使用SCHWINDSIRIUS设备评估的眼表炎症风险评估（OSIE）（SCHWINDeye-tech-solutionsGmbH，Kleinostheim,德国)。
结果：本研究记录了与DED和MGD相关的主观和客观症状的显著改善。通过EFT测量的主观症状显示平均增加9.74点（范围-10至28，标准偏差[SD]±7.54），表明症状减少。泪膜稳定性的客观措施，以NIABUT为代表,平均增加4.04s（范围-15.00至14.40，SD±4.91）。泪膜稳定性评价(TFSE)得分平均下降229.12分(范围-1775~528,SD±384.94),提示泪膜稳定性增强。OSIE1型显示炎症减少，百分比下降4.98%(范围-45~5,SD±7.33)。此外,OSIE捕获时间平均减少3.25s(范围-27~22,SD±10.35),进一步表明眼表健康的改善。
结论：IPL治疗被证明是一种有希望的，通过有效控制症状和稳定泪膜改善DED患者生活质量的无创方法。研究结果支持使用IPL作为与MGD相关的DED的可持续治疗方式。
方法：对110名接受IPL治疗的参与者进行了回顾性病例系列研究。评估包括眼睛体能测试（EFT）以评估主观症状，以及使用Tearcheck®设备的客观测量(ESW视觉，胡丹,法国）非侵入性首次分手时间（NIFBUT），无创平均破裂时间(NIABUT)，中央撕裂半月板高度（CTMH），最薄泪液弯月面高度（TTMH），和使用SCHWINDSIRIUS设备评估的眼表炎症风险评估（OSIE）（SCHWINDeye-tech-solutionsGmbH，Kleinostheim,德国)。
结果：本研究记录了与DED和MGD相关的主观和客观症状的显著改善。通过EFT测量的主观症状显示平均增加9.74点（范围-10至28，标准偏差[SD]±7.54），表明症状减少。泪膜稳定性的客观措施，以NIABUT为代表,平均增加4.04s（范围-15.00至14.40，SD±4.91）。泪膜稳定性评价(TFSE)得分平均下降229.12分(范围-1775~528,SD±384.94),提示泪膜稳定性增强。OSIE1型显示炎症减少，百分比下降4.98%(范围-45~5,SD±7.33)。此外,OSIE捕获时间平均减少3.25s(范围-27~22,SD±10.35),进一步表明眼表健康的改善。
结论：IPL治疗被证明是一种有希望的，通过有效控制症状和稳定泪膜改善DED患者生活质量的无创方法。研究结果支持使用IPL作为与MGD相关的DED的可持续治疗方式。
